Page 92 - Binder2

What once looked like isolated therapy failures are now
starting to align as a pattern—a pattern that reveals not just
a scientific problem, but a design flaw across an entire
generation of biologics.

And patterns, once named, become impossible to ignore.

2.9 – What We Overlooked

Biologics are one of the most impressive accomplishments
in the history of medicine. They have turned once-
devastating conditions into chronic, manageable diseases.
For millions of patients, they’ve restored function, delayed
decline, and delivered hope where conventional therapies
had failed. They are not the villains of this story—they are
the product of decades of innovation, collaboration, and
ambition.

But even the most celebrated advances can carry blind
spots. And in the case of biologics, that blind spot was the
immune system itself.

We built biologics to work—to bind, to block, to suppress.
And we succeeded. We engineered monoclonal antibodies
that could target inflammatory cytokines with laser-like
precision. We cloned fusion proteins that could intervene in
immune signaling with elegance and force. We validated
them in trials, secured approval, and built billion-dollar
franchises around them.

What we didn’t do—what we systemically failed to do—
was ask how these molecules would fare over time in the

90